Dr. Falk Pharma GmbH: Colitis trials

The registry lists 10 Colitis studies with Dr. Falk Pharma GmbH as lead sponsor. 0 are open to participants now and 0 have results posted.

Phase 2 1Phase 3 9(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Budesonide 9 mg Capsules in Active UCCompletedNCT02550418Phase 2
• Phosphatidylcholine (LT-02) vs. Placebo vs. Mesalamine for Maintenance of Remission in Ulcerative Colitis (PROTECT-2)CompletedNCT02280629Phase 3
• Phosphatidylcholine (LT-02) for Induction of Remission in Ulcerative ColitisTerminatedNCT02142725Phase 3
• Budesonide for Induction of Remission in Incomplete Microscopic ColitisCompletedNCT02142634Phase 3
• SOIBD Collagenous Colitis Maintenance StudyCompletedNCT01278082Phase 3
• Budesonide Versus Mesalazine Versus Placebo in Lymphocytic ColitisCompletedNCT01209208Phase 3
• Budesonide Capsules Versus Mesalazine Granules in Active Ulcerative Colitis (UC)CompletedNCT00747110Phase 3
• Once Daily (OD) Versus Three Times Daily (TID) Dosing With Mesalazine Granules for Prevention of Recurrence of Ulcerative Colitis (UC)CompletedNCT00746447Phase 3
• Budesonide Capsules vs. Mesalazine Granules vs. Placebo in Collagenous ColitisCompletedNCT00450086Phase 3
• OD vs. TID Dosing With Mesalazine Granules in Active Ulcerative ColitisCompletedNCT00449722Phase 3